KKR will acquire Integer Holdings for $5.7 billion in cash, taking the medical-device contract manufacturer private in a transaction announced Monday. The deal removes one of the largest independent outsourcers of cardiac rhythm and neuromodulation components from public markets at a moment when device OEMs face margin pressure and regulatory complexity.

Integer manufactures high-precision components for implantable devices—pacemaker batteries, neurostimulator leads, catheter assemblies—sold to firms including Medtronic, Boston Scientific, and Abbott. The Plano operation posted $1.52 billion in trailing twelve-month revenue with EBITDA margins near 19%, concentrated in segments where scale and regulatory moat matter more than innovation velocity. KKR is paying roughly 10.2x forward EBITDA based on sell-side consensus, a 22% premium to where Integer traded three months ago, before merger speculation began circulating in July.

The thesis is consolidation arbitrage in a fragmented contract manufacturing layer. Device OEMs have spent the past eighteen months pruning supplier rosters to manage quality audits and traceability requirements under the EU Medical Device Regulation. Integer holds FDA-registered and ISO 13485-certified facilities across five countries, a compliance infrastructure that takes seven to nine years to replicate. KKR sees a $180–220 million organic capex runway to add cleanroom capacity in Poland and Malaysia, plus tuck-in M&A among sub-scale shops in the neuromodulation and structural heart segments. The firm ran a similar playbook with Envision Healthcare, though that deal unraveled in refinancing. Here the balance sheet is cleaner—Integer carries $680 million in net debt, manageable against $290 million in annual free cash flow.

Two second-order effects matter for allocators. First, this validates private equity's continued appetite for healthcare services at the component layer, where regulatory capture substitutes for technology risk. Expect follow-on bids for peer manufacturers like Greatbatch-adjacent plays and specialty catheter suppliers trading below 9x EBITDA. Second, the deal signals that large-cap PE sees a two- to three-year window before tariffs or reshoring mandates disrupt Asian supply chains for Class III devices. KKR is not betting on innovation—it is betting on the cost of switching suppliers in a duopoly customer base.

Operators should watch Integer's Q3 earnings in late October for any pull-forward of customer commitments or pricing adjustments ahead of the close. The transaction requires HSR clearance and foreign investment review in Poland and Switzerland, likely resolved by late Q1 2027. If KKR finances with more than 55% leverage, refinancing risk enters the picture within eighteen months.

The deal closes a twelve-month window in which three contract manufacturers—Integer, Paragon28's supplier base, and a European precision machining group—went private at premiums above 20%. The common thread is not growth. It is the option value of being the last scaled supplier when the next regulatory tightening arrives.